Literature DB >> 21107989

Integrating molecular docking, DFT and CoMFA/CoMSIA approaches for a series of naphthoquinone fused cyclic α-aminophosphonates that act as novel topoisomerase II inhibitors.

Yi Ma1, Jian-Guo Wang, Bin Wang, Zheng-Ming Li.   

Abstract

Since they are potential topoisomerase II (Topo II) inhibitors, naphthoquinone fused cyclic α-aminophosphonates display anticancer activity. In order to explore the inhibitory mechanisms of these compounds, they were docked into the active site of Topo II structure, which allowed their probable binding modes to be predicted. Some meaningful results concerning their structure-activity relationships were obtained from density functional theory calculations. Models based on quantitative comparative molecular field analysis and comparative molecular similarity index analysis were derived for the steric, electrostatic, hydrophobic and H-bonding features of the compounds. The present study provides valuable results that enhance our understanding of the anticancer activities of these inhibitors and will aid the rational drug design of novel Topo II inhibitors in the future.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21107989     DOI: 10.1007/s00894-010-0898-y

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  34 in total

1.  3D-QSAR model of flavonoids binding at benzodiazepine site in GABAA receptors.

Authors:  X Huang; T Liu; J Gu; X Luo; R Ji; Y Cao; H Xue; J T Wong; B L Wong; G Pei; H Jiang; K Chen
Journal:  J Med Chem       Date:  2001-06-07       Impact factor: 7.446

Review 2.  Antitumor triptycene bisquinones: a novel synthetic class of dual inhibitors of DNA topoisomerase I and II activities.

Authors:  Buna Wang; Elisabeth M Perchellet; Yang Wang; Masafumi Tamura; Duy H Hua; Jean-Pierre H Perchellet
Journal:  Anticancer Drugs       Date:  2003-08       Impact factor: 2.248

3.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes.

Authors:  M D Eldridge; C W Murray; T R Auton; G V Paolini; R P Mee
Journal:  J Comput Aided Mol Des       Date:  1997-09       Impact factor: 3.686

4.  3D-QSAR analysis on benzazole derivatives as eukaryotic topoisomerase II inhibitors by using comparative molecular field analysis method.

Authors:  Ozlem Temiz-Arpaci; Betul Tekiner-Gulbas; Ilkay Yildiz; Esin Aki-Sener; Ismail Yalcin
Journal:  Bioorg Med Chem       Date:  2005-06-29       Impact factor: 3.641

5.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity.

Authors:  G Klebe; U Abraham; T Mietzner
Journal:  J Med Chem       Date:  1994-11-25       Impact factor: 7.446

Review 6.  DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide.

Authors:  P B Jensen; M Sehested
Journal:  Biochem Pharmacol       Date:  1997-10-01       Impact factor: 5.858

7.  Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system.

Authors:  Suna Ertongur; Stephan Lang; Brigitte Mack; Katja Wosikowski; Bernd Muehlenweg; Olivier Gires
Journal:  Int J Cancer       Date:  2004-07-20       Impact factor: 7.396

Review 8.  Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation.

Authors:  Ling-hua Meng; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2007-09       Impact factor: 6.150

9.  Synthesis, bioactivity, theoretical and molecular docking study of 1-cyano-N-substituted-cyclopropanecarboxamide as ketol-acid reductoisomerase inhibitor.

Authors:  Xing-Hai Liu; Pei-Quan Chen; Bao-Lei Wang; Yong-Hong Li; Su-Hua Wang; Zheng-Ming Li
Journal:  Bioorg Med Chem Lett       Date:  2007-04-06       Impact factor: 2.823

Review 10.  Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

Authors:  Mohit Trikha; Robert Corringham; Bernard Klein; Jean-François Rossi
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

View more
  5 in total

1.  Identification of potent catalytic inhibitors of human DNA topoisomerase II by structure-based virtual screening.

Authors:  Guoqiang Dong; Ying Wu; Ying Sun; Na Liu; Shanchao Wu; Wannian Zhang; Chunquan Sheng
Journal:  Medchemcomm       Date:  2018-05-24       Impact factor: 3.597

Review 2.  Proposal of Dual Inhibitor Targeting ATPase Domains of Topoisomerase II and Heat Shock Protein 90.

Authors:  Kyu-Yeon Jun; Youngjoo Kwon
Journal:  Biomol Ther (Seoul)       Date:  2016-09-01       Impact factor: 4.634

3.  Chemical synthesis, crystal structure, versatile evaluation of their biological activities and molecular simulations of novel pyrithiobac derivatives.

Authors:  Ren-Jun Wu; Kai-Xuan Zhou; Haijin Yang; Guo-Qing Song; Yong-Hong Li; Jia-Xin Fu; Xiao Zhang; Shu-Jing Yu; Li-Zhong Wang; Li-Xia Xiong; Cong-Wei Niu; Fu-Hang Song; Haitao Yang; Jian-Guo Wang
Journal:  Eur J Med Chem       Date:  2019-02-14       Impact factor: 6.514

4.  Theoretical exploration on structures, bonding aspects and molecular docking of α-aminophosphonate ligated copper complexes against SARS-CoV-2 proteases.

Authors:  Oval Yadav; Manjeet Kumar; Himanshi Mittal; Kiran Yadav; Veronique Seidel; Azaj Ansari
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

5.  Cytotoxic effect and molecular docking of 4-ethoxycarbonylmethyl-1-(piperidin-4-ylcarbonyl)-thiosemicarbazide--a novel topoisomerase II inhibitor.

Authors:  Agata Siwek; Paweł Stączek; Monika Wujec; Krzysztof Bielawski; Anna Bielawska; Piotr Paneth
Journal:  J Mol Model       Date:  2012-11-28       Impact factor: 1.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.